OncologyImmuno-oncologyImmunology & inflammation PopPK

Cemiplimab time-varying population PK

Reference paper ↗

A two-compartment population PK model representing cemiplimab exposure, covariate-dependent disposition, and gradual time variation in clearance.

Therapeutic
Cemiplimab, Libtayo, REGN2810, cemiplimab-rwlc
Modality
Monoclonal antibody
Target
PD-1 / PDCD1
Disease
Advanced malignancies
Model type
PopPK

Complete model workspace

Checking workspace access…

Parameters
23
States
4
Equations
4
Derived outputs
11

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Typical 3 mg/kg every 2 weeks IV regimen

How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure? Explore this intervention regimen through Central cemiplimab concentration, Cumulative cemiplimab exposure, Individual clearance, Time-varying clearance factor.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–168 day; step 7

InputDefaultAvailable range
Typical clearance0.29 L/day0.145–0.435 L/day
Typical central distribution volume3.32 L1.66–4.98 L
Typical intercompartmental clearance0.638 L/day0.319–0.957 L/day
Typical peripheral distribution volume1.65 L0.825–2.475 L
Time to half-maximal change28.9 day14.45–43.35 day

Expected readouts

Central cemiplimab concentration · Exposure (AUC) (day*mg/L) · Individual clearance · Time varying clearance factor

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 23 declared model parameters.

More key parameters (1)

How the model represents the biology

A two-compartment population PK model representing cemiplimab exposure, covariate-dependent disposition, and gradual time variation in clearance.

How do covariates and elapsed time shape cemiplimab clearance and exposure?Intravenous cemiplimab enters a central pool, exchanges with a peripheral pool, undergoes covariate- and time-adjusted clearance, and accumulates central exposure. Weight, BMI, albumin, IgG, ALT, and an empirical elapsed-time Hill factor modify disposition.BIOLOGY OVERVIEWHow do covariates and elapsed time shape cemiplimab clearance and exposure?IV cemiplimabInfusion to central amountCentral exposureCemiplimab concentrationPeripheral poolReversible distributionClinical covariatesWeight, BMI, albumin, IgG, ALTElapsed-time factorEmpirical Hill functionTime-varying clearanceAdjusted central lossCumulative exposureCentral concentration integralPRIMARY READOUTSCentral cemiplimab concentrationCentral cemiplimab concent…Cumulative exposureCumulative exposureIndividual clearanceIndividual clearanceTime factorTime factor

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: PD-1 binding, target engagement, antitumor response, nonlinear or target-mediated clearance, and biological response-to-clearance feedback are not represented.

Modeled relationships (7)
  • IV cemiplimab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Clinical covariates → Central exposure: scales volume (modulation)
  • Clinical covariates → Time-varying clearance: scales CL (modulation)
  • Elapsed-time factor → Time-varying clearance: changes CL(t) (modulation)
  • Central exposure → Time-varying clearance: adjusted CL (loss)
  • Central exposure → Cumulative exposure: integrates C (production)

Modeled relationships: IV cemiplimab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Clinical covariates to Central exposure: scales volume (modulation); Clinical covariates to Time-varying clearance: scales CL (modulation); Elapsed-time factor to Time-varying clearance: changes CL(t) (modulation); Central exposure to Time-varying clearance: adjusted CL (loss); Central exposure to Cumulative exposure: integrates C (production).

Primary readouts: Central cemiplimab concentration; Cumulative exposure; Individual clearance; Time factor.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID yang_2021_cemiplimab_advanced_malignancies_poppk.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics